insights_auto
Zašto je 2359 pao 2,19%?
Istražite detaljnijechevron_right
2359:HKG
WuXi AppTec Ord Shs H
196,20 HKD
arrow_downward
−2,19%(−4,40) 1D
16. lis, 16:08:14 GMT+8 · HKD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 2359...
Otvori
203,80 HKD
Najviša
209,00 HKD
Najniža
185,00 HKD
Trž. kap.
544,52 mlr.
Prosj. kol.
3,91 mil.
Količina
10,16 mil.
Dividenda
1,22 %
Kvartalna dividenda
0,60 HKD
Datum nakon isplate dividende
4. ruj 2026.
P/E omjer
23,98
52-tjed. najviša
219,20 HKD
52-tjed. najniža
96,70 HKD
EPS
8,18 HKD
Broj djelatnika
36 tis.
Otvori
203,80 HKD
Najviša
209,00 HKD
Najniža
185,00 HKD
Trž. kap.
544,52 mlr.
Prosj. kol.
3,91 mil.
Količina
10,16 mil.
Dividenda
1,22 %
Kvartalna dividenda
0,60 HKD
Datum nakon isplate dividende
4. ruj 2026.
P/E omjer
23,98
52-tjed. najviša
219,20 HKD
52-tjed. najniža
96,70 HKD
EPS
8,18 HKD
Broj djelatnika
36 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
ad-hoc-news.de
·
prije 5 sati
WuXi AppTec earns EcoVadis gold: what it means for WuXi AppTec stock
Profil
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
WuXi AppTec Ord Shs H – informacije
Glavni izvršni direktorSteve Yang | Ge Li
Zaposlenici35,6 tis.
Osnovano1. pro 2000.
Sjedište-
Sektor-
Web-lokacijawuxiapptec.com.cn